FDA Approves SABRIL — Lundbeck Pharmaceuticals LLC

# FDA Approves Lundbeck's SABRIL (Vigabatrin) for Oral Use Lundbeck Pharmaceuticals LLC has received FDA approval for SABRIL (vigabatrin) oral formulation, expanding the company's portfolio in the anti-epilepsy market and positioning it to capture market share in a therapeutic category with limited treatment options. The approval of the oral route represents a significant convenience advantage over existing formulations, potentially driving adoption among patients and clinicians seeking more accessible administration methods.